Related references
Note: Only part of the references are listed.Development of Mcl-1 inhibitors for cancer therapy
Arvind Negi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma
Karina Biserova et al.
CELLS (2021)
Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs
Xin Yi Wong et al.
ACS NANO (2020)
Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer
Danielle M. Valcourt et al.
ACS NANO (2020)
Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy
Yanjie Liu et al.
NANO LETTERS (2020)
Albumin-Based Nanotheranostic Probe with Hypoxia Alleviating Potentiates Synchronous Multimodal Imaging and Phototherapy for Glioma
Zhenzhen Yang et al.
ACS NANO (2020)
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
Yonghan He et al.
NATURE COMMUNICATIONS (2020)
Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma
Derek Reichel et al.
ACS NANO (2020)
Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
Enyuan Shang et al.
CANCERS (2020)
Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates
Mahwash Mukhtar et al.
CHEMOSENSORS (2020)
Clinical cancer nanomedicine
Joy Wolfram et al.
NANO TODAY (2019)
Challenges to curing primary brain tumours
Kenneth Aldape et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Recent advances in the development of Mcl-1 inhibitors for cancer therapy
Alexander W. Hird et al.
PHARMACOLOGY & THERAPEUTICS (2019)
BCL-2 family isoforms in apoptosis and cancer
Chloe F. A. Warren et al.
CELL DEATH & DISEASE (2019)
Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma
Marc-Eric Halatsch et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Cyril Neftel et al.
CELL (2019)
Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice
Huazhen Qin et al.
MOLECULAR PHARMACEUTICS (2019)
Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Zeinab Sharifi et al.
CLINICAL CANCER RESEARCH (2019)
Red Blood Cell Membrane Processing for Biomedical Applications
Luigia Rossi et al.
FRONTIERS IN PHYSIOLOGY (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
T-C Teh et al.
LEUKEMIA (2018)
Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents
Yichao Wan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
Yiru Zhang et al.
SCIENTIFIC REPORTS (2018)
Primary brain tumours in adults
Sarah Lapointe et al.
LANCET (2018)
Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma
Yu Jiang et al.
ACS NANO (2018)
Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine
Yan Zou et al.
ADVANCED MATERIALS (2018)
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron et al.
NATURE COMMUNICATIONS (2018)
Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma
Georg Karpel-Massler et al.
EXPERT OPINION ON DRUG DISCOVERY (2017)
Overcoming therapeutic resistance in glioblastoma: the way forward
Satoru Osuka et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Intra-tumor heterogeneity from a cancer stem cell perspective
Pramudita R. Prasetyanti et al.
MOLECULAR CANCER (2017)
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
Nai-Jia Huang et al.
NATURE COMMUNICATIONS (2017)
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Georg Karpel-Massler et al.
NATURE COMMUNICATIONS (2017)
Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications
Silvia Anahi Valdes-Rives et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
Yi Zhu et al.
AGING CELL (2016)
Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo
Georg Karpel-Massler et al.
ONCOTARGET (2016)
A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study
Mathilde Hunault-Berger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update
Waseem Ahmad Siddiqui et al.
ARCHIVES OF TOXICOLOGY (2015)
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Thomas J. Kipps et al.
LEUKEMIA & LYMPHOMA (2015)
MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Yu Xiao et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Elvin Blanco et al.
NATURE BIOTECHNOLOGY (2015)
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
J. D. Leverson et al.
CELL DEATH & DISEASE (2015)
Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
Georg Karpel-Massler et al.
ONCOTARGET (2015)
PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD
Fresia Pareja et al.
MOLECULAR CANCER RESEARCH (2014)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E. Czabotar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity
D. Schmid et al.
CELL DEATH & DISEASE (2014)
Apoptosis and Molecular Targeting Therapy in Cancer
Mohamed Hassan et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Metabolism of Nanomaterials in Vivo: Blood Circulation and Organ Clearance
Bing Wang et al.
ACCOUNTS OF CHEMICAL RESEARCH (2013)
Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles
Ronnie H. Fang et al.
NANOSCALE (2013)
Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier
Daren Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Role of Bcl-2 family proteins and caspases in the regulation of apoptosis
Mohammad Shamsul Ola et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
Che-Ming J. Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization
O. Jameel Shah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Min H. Kang et al.
CLINICAL CANCER RESEARCH (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Anti-apoptosis mechanisms in malignant gliomas
David S. Ziegler et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins
K. E. Tagscherer et al.
ONCOGENE (2008)
The Bcl-2 apoptotic switch in cancer development and therapy
J. M. Adams et al.
ONCOGENE (2007)
Bcl-2 family inhibitor ABT-263 shows significant but reversible thrombocytopenia in mice.
Alex R. Shoemaker et al.
BLOOD (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1
JE Croy et al.
BIOCHEMISTRY (2004)
Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy
JK Smith et al.
ONCOLOGY RESEARCH (2004)
Share Paper
